Luoxin Pharmaceuticals Group Stock Co Ltd (002793) - Total Liabilities
Based on the latest financial reports, Luoxin Pharmaceuticals Group Stock Co Ltd (002793) has total liabilities worth CN¥2.39 Billion CNY (≈ $350.31 Million USD) as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore Luoxin Pharmaceuticals Group Stock Co Lt equity growth rate to track the company's year-over-year net asset growth rate.
Luoxin Pharmaceuticals Group Stock Co Ltd - Total Liabilities Trend (2011–2025)
This chart illustrates how Luoxin Pharmaceuticals Group Stock Co Ltd's total liabilities have evolved over time, based on quarterly financial data. See 002793 free cash flow to operating cash ratio to measure how efficiently the company converts operating cash flow to free cash.
Luoxin Pharmaceuticals Group Stock Co Ltd Competitors by Total Liabilities
The table below lists competitors of Luoxin Pharmaceuticals Group Stock Co Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Kura Oncology Inc
NASDAQ:KURA
|
USA | $544.67 Million |
|
Sunrise Group Co Ltd
SHE:002752
|
China | CN¥4.15 Billion |
|
Aspen Group
AU:APZ
|
Australia | AU$287.58 Million |
|
Beijing Shenzhou Aerospace Software Technology Co. Ltd. A
SHG:688562
|
China | CN¥1.20 Billion |
|
Unilumin Group Co Ltd
SHE:300232
|
China | CN¥5.24 Billion |
|
Anhui Estone Materials Technology Co Ltd
SHG:688733
|
China | CN¥1.29 Billion |
|
Wuhan Zhongyuan Huadian Sci Tech
SHE:300018
|
China | CN¥275.13 Million |
|
Shenzhen Topraysolar Co Ltd
SHE:002218
|
China | CN¥2.60 Billion |
Liability Composition Analysis (2011–2025)
This chart breaks down Luoxin Pharmaceuticals Group Stock Co Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Luoxin Pharmaceuticals Group Stock Co Lt market capitalisation.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.76 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 2.18 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.67 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Luoxin Pharmaceuticals Group Stock Co Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Luoxin Pharmaceuticals Group Stock Co Ltd (2011–2025)
The table below shows the annual total liabilities of Luoxin Pharmaceuticals Group Stock Co Ltd from 2011 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | CN¥2.49 Billion ≈ $364.31 Million |
-13.45% |
| 2024-12-31 | CN¥2.88 Billion ≈ $420.93 Million |
+13.03% |
| 2023-12-31 | CN¥2.54 Billion ≈ $372.41 Million |
-46.99% |
| 2022-12-31 | CN¥4.80 Billion ≈ $702.59 Million |
+0.85% |
| 2021-12-31 | CN¥4.76 Billion ≈ $696.69 Million |
+41.22% |
| 2020-12-31 | CN¥3.37 Billion ≈ $493.33 Million |
-3.64% |
| 2019-12-31 | CN¥3.50 Billion ≈ $511.99 Million |
+611.36% |
| 2018-12-31 | CN¥491.85 Million ≈ $71.97 Million |
+239.81% |
| 2017-12-31 | CN¥144.74 Million ≈ $21.18 Million |
+26.35% |
| 2016-12-31 | CN¥114.56 Million ≈ $16.76 Million |
-45.47% |
| 2015-12-31 | CN¥210.10 Million ≈ $30.74 Million |
+58.69% |
| 2014-12-31 | CN¥132.40 Million ≈ $19.37 Million |
+18.42% |
| 2013-12-31 | CN¥111.80 Million ≈ $16.36 Million |
-32.96% |
| 2012-12-31 | CN¥166.77 Million ≈ $24.40 Million |
+38.89% |
| 2011-12-31 | CN¥120.07 Million ≈ $17.57 Million |
-- |
About Luoxin Pharmaceuticals Group Stock Co Ltd
Luoxin Pharmaceuticals Group Stock Co., Ltd. engages in the research and development, manufacture, and trading of drugs in China. The company provides antiviral, anti-infective, respiratory and digestive system, nervous and endocrine system, cardiovascular system, oncology, and anti-allergic APIs and intermediates, as well as antipyretic, analgesics, and anti-inflammatory APIs and intermediates. … Read more